期刊文献+

美国药品安全突发事件的预防与应对机制 被引量:6

America's Emergency Precautions and Response Mechanism of Drug Safety
原文传递
导出
摘要 药品不同于一般的商品,一方面它关系着全民的健康与福祉;另一方面复杂的成分和高度专业化的使用又使得药品不良反应带来的安全隐患难以觉察,一旦爆发则不仅给用药患者的生命健康带来重大伤害,某种程度上甚至会造成社会公众的恐慌。因此对药品不良反应突发事件的预防与应对,是现代各国政府监管的重中之重。美国是最早开展药品安全监管的国家,而其以FDA为核心的药品安全监管体系,则以先进的监管模式、广泛的数据来源和灵敏的反应对策闻名于世,堪为模范。 This article aims to conduct a preliminary study of the mechanism.The full text can be divided into three parts:the first part introduces America's complete system of drug safety from the perspective of organizational and monitoring system;the second part analyzes the two typical cases(Cerivastatin Event and Vioxx Event) reflecting advantages and disadvantages of the system;the third part is on a reflection and reconstruction of the existing system.This article attempts to fully demonstrate advantages and disadvantages of the monitoring mechanism of FDA drug safety.Its intention is to provide some experience and lessons for perfecting China 's emergency response mechanism of drug adverse reaction.
作者 何兵 昌君
出处 《中国政法大学学报》 2008年第3期42-54,159,共14页 Journal Of CUPL
基金 国家社科基金重大项目"法治背景下的社会预警机制和应急管理体系研究"阶段性成果
  • 相关文献

参考文献35

  • 1董怡.从罗非昔布撤市看药品不良反应及其监测[J].中国药物警戒,2005,2(1):14-15. 被引量:2
  • 2F.D.A.Official Admits‘Lapses’on Vioxx. http://www.nytimes.com/2005/03/02/politics/02fda.html_r=1&ex=1189915200&en=3e0612040887ae36&ei=5070&oref=slogin .
  • 3Maurice Hinchey.THE FIGHT TO SAFEGUARD AMERICAN DRUG SAFETY IN THE TWENTY-FIRST CENTURY. Hofstra Law Review . 2006
  • 4FDA Fact Sheet. http://www.fda.gov/oc/factsheets/drugsafety.html . 2005
  • 5The FDA’s Reputation with the General Public is Under Assault. http://www.marketresearchworld.net/index.php-option=com_content&task=view&id=711&Itemid=48 .
  • 6Curt D.Furberg,MD,PhD,Arthur A.Levin,Peter A.Gross,MD,Robyn S.Shapiro,JD,Brian L.Strom,MD.The FDA and Drug Safety:A Proposal for Sweeping Changes. http://www.ahrp.org/cms/content/view/358/28/ .
  • 7Curt D.Furberg,MD,PhD,Arthur A.Levin,Peter A.Gross,MD,Robyn S.Shapiro,JD,Brian L.Strom,MD.The FDA and Drug Safety:A Proposal for Sweeping Changes. http://www.ahrp.org/cms/content/view/358/28/ .
  • 8Susan Okie,M.D.What Ails the FDA. http://content.nejm.org/cgi/content/full/352/11/1063 .
  • 9http://content.nejm.org/cgi/content/full/352/11/1063/F1 .
  • 10Maurice Hinchey.THE FIGHT TO SAFEGUARD AMERICAN DRUG SAFETY IN THE TWENTY-FIRST CENTURY. Hofstra Law Review . 2006

二级参考文献7

  • 1默克公司主动从全球市场撤回罗非昔布(万络)[J].中国药物警戒,2004,1(2):59-60. 被引量:3
  • 2[1]Bombardier C,Laine L,Recin Aet al Comparison of upper gastrointestinal Toxicity of Rofecoxib and naproxen in patients with RA[J].NEJM,2000,343:1520-1528.
  • 3[2]Konstam MA,Weir MR,Reicin A et al:Cardivascular thrombotic events in controlled clinical trials of Rofecoxib[J].Circulation,2001,104:2280-2288.
  • 4[3]Mamdani M,Rochon P,Juurlink DN et al:Effects of selective cox-2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly[J].Arch Int Med,2003,163:481-486.
  • 5[4]Ray WA.Stein CM,Daugherty JR et al:Cox-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease[J].Lancet,2002,360:1071-1073.
  • 6[5]Solomon DH,Schneeweiss S,Glynn RJ et al:Relationship between selective cox-2 inhibitors and acute myocardial infarction in older adults[J].Circulation,2004,109:2068-2073.
  • 7[6]Graham DJ,Campen DH,Cheetham C et al:Risk of acute myocardial infarction and sudden cardiac death with use of cox-2 selective and non-selective[M].NSAIDss ACC,2004.

共引文献1

同被引文献67

引证文献6

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部